Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 02:01 pm IST
Share
Anhui Anke Biotechnology (Group) Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 533.36 million compared to CNY 484.83 million a year ago. Revenue was CNY 533.36 million compared to CNY 484.83 million a year ago. Net income was CNY 172.9 million compared to CNY 125.58 million a year ago. Basic earnings per share from continuing operations was CNY 0.1055 compared to CNY 0.0767 a year ago. Diluted earnings per share from continuing operations was CNY 0.1055 compared to CNY 0.0767 a year ago.
Anhui Anke Biotechnology (Group) Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of biological products, Chinese patent drugs, chemical synthetic drugs, peptide drugs and nucleic acid detection products. The Companyâs main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The Company distributes its products in domestic market and to overseas markets.
ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. 
